Tofacitinib, which inhibits JAK1, JAK3, and to a slightly lesser extent JAK2, therefore may function to reduce or inhibit inflammatory pathways that lead to rheumatoid nodule formation. The gene discussed is JAK1; the disease is rheumatoid arthritis.